FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048440199> ?p ?o ?g. }

• W3048440199 endingPage "102268" @default.
• W3048440199 startingPage "102268" @default.
• W3048440199 abstract "Increasing evidence suggests that metabolic dysfunctions are at the roots of neurodegenerative disorders such as Alzheimer’s disease (AD). In particular, defects in cerebral glucose metabolism, which have been often noted even before the occurrence of clinical symptoms and histopathological lesions, are now regarded as critical contributors to the pathogenesis of AD. Hence, the stimulation of energy metabolism, by enhancing the availability of specific metabolites, might be an alternative way to improve ATP synthesis and to positively affect AD progression. For instance, glutamate may serve as an intermediary metabolite for ATP synthesis through the tricarboxylic acid (TCA) cycle and the oxidative phosphorylation. We have recently shown that two transporters are critical for the anaplerotic use of glutamate: the Na+-dependent Excitatory Amino Acids Carrier 1 (EAAC1) and the Na+-Ca2+ exchanger 1 (NCX1). Therefore, in the present study, we established an AD-like phenotype by perturbing glucose metabolism in both primary rat cortical neurons and retinoic acid (RA)-differentiated SH-SY5Y cells, and we explored the potential of glutamate to halt cell damage by monitoring neurotoxicity, AD markers, ATP synthesis, cytosolic Ca2+ levels and EAAC1/NCX1 functional activities. We found that glutamate significantly increased ATP production and cell survival, reduced the increase of AD biomarkers (amyloid β protein and the hyperphosphorylated form of tau protein), and recovered the increase of NCX reverse-mode activity. The RNA silencing of either EAAC1 or NCX1 caused the loss of the beneficial effects of glutamate, suggesting the requirement of a functional interplay between these transporters for glutamate-induced protection. Remarkably, our results indicate, as proof‐of‐principle, that facilitating the use of alternative fuels, like glutamate, may be an effective approach to overcome deficits in glucose utilization and significantly slow down neuronal degenerative process in AD." @default.
• W3048440199 created "2020-08-18" @default.
• W3048440199 creator A5021962931 @default.
• W3048440199 creator A5068272017 @default.
• W3048440199 creator A5072788559 @default.
• W3048440199 creator A5073869734 @default.
• W3048440199 creator A5084569772 @default.
• W3048440199 date "2020-11-01" @default.
• W3048440199 modified "2023-10-10" @default.
• W3048440199 title "NCX1 and EAAC1 transporters are involved in the protective action of glutamate in an in vitro Alzheimer's disease-like model" @default.
• W3048440199 cites W1548621866 @default.
• W3048440199 cites W1580327310 @default.
• W3048440199 cites W1593025724 @default.
• W3048440199 cites W1965694882 @default.
• W3048440199 cites W1965714713 @default.
• W3048440199 cites W1969913349 @default.
• W3048440199 cites W1972030842 @default.
• W3048440199 cites W1973245046 @default.
• W3048440199 cites W1973500410 @default.
• W3048440199 cites W1974994925 @default.
• W3048440199 cites W1980184756 @default.
• W3048440199 cites W1981526622 @default.
• W3048440199 cites W1983603578 @default.
• W3048440199 cites W1985344555 @default.
• W3048440199 cites W1986660175 @default.
• W3048440199 cites W2005748599 @default.
• W3048440199 cites W2005805532 @default.
• W3048440199 cites W2009543173 @default.
• W3048440199 cites W2016374740 @default.
• W3048440199 cites W2016521213 @default.
• W3048440199 cites W2017349282 @default.
• W3048440199 cites W2020318455 @default.
• W3048440199 cites W2025478209 @default.
• W3048440199 cites W2038468721 @default.
• W3048440199 cites W2047373421 @default.
• W3048440199 cites W2065878752 @default.
• W3048440199 cites W2070754102 @default.
• W3048440199 cites W2076199082 @default.
• W3048440199 cites W2077136490 @default.
• W3048440199 cites W2087987630 @default.
• W3048440199 cites W2096219863 @default.
• W3048440199 cites W2097724095 @default.
• W3048440199 cites W2101840868 @default.
• W3048440199 cites W2115884335 @default.
• W3048440199 cites W2123715446 @default.
• W3048440199 cites W2125155338 @default.
• W3048440199 cites W2125473951 @default.
• W3048440199 cites W2138328666 @default.
• W3048440199 cites W2139472024 @default.
• W3048440199 cites W2140616438 @default.
• W3048440199 cites W2143373379 @default.
• W3048440199 cites W2147691616 @default.
• W3048440199 cites W2148196878 @default.
• W3048440199 cites W2158402798 @default.
• W3048440199 cites W2163859059 @default.
• W3048440199 cites W2175337105 @default.
• W3048440199 cites W2234045142 @default.
• W3048440199 cites W2237434258 @default.
• W3048440199 cites W2288296253 @default.
• W3048440199 cites W2335815721 @default.
• W3048440199 cites W2340062477 @default.
• W3048440199 cites W2341769195 @default.
• W3048440199 cites W2415391841 @default.
• W3048440199 cites W2419649294 @default.
• W3048440199 cites W2517641217 @default.
• W3048440199 cites W2522744939 @default.
• W3048440199 cites W2553070815 @default.
• W3048440199 cites W2591756301 @default.
• W3048440199 cites W2610960352 @default.
• W3048440199 cites W2761440302 @default.
• W3048440199 cites W2767683338 @default.
• W3048440199 cites W2777525962 @default.
• W3048440199 cites W2786962139 @default.
• W3048440199 cites W2810649171 @default.
• W3048440199 cites W2885855497 @default.
• W3048440199 cites W2891726711 @default.
• W3048440199 cites W2908133680 @default.
• W3048440199 cites W2911493122 @default.
• W3048440199 cites W2913920467 @default.
• W3048440199 cites W2964135466 @default.
• W3048440199 cites W2978698290 @default.
• W3048440199 cites W2985169208 @default.
• W3048440199 cites W2986012156 @default.
• W3048440199 cites W2998836014 @default.
• W3048440199 cites W2999502891 @default.
• W3048440199 cites W3004822388 @default.
• W3048440199 cites W3025955412 @default.
• W3048440199 cites W4210979710 @default.
• W3048440199 cites W48248669 @default.
• W3048440199 doi "https://doi.org/10.1016/j.ceca.2020.102268" @default.
• W3048440199 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32827867" @default.
• W3048440199 hasPublicationYear "2020" @default.
• W3048440199 type Work @default.
• W3048440199 sameAs 3048440199 @default.
• W3048440199 citedByCount "11" @default.
• W3048440199 countsByYear W30484401992020 @default.
• W3048440199 countsByYear W30484401992021 @default.
• W3048440199 countsByYear W30484401992022 @default.

• next